Machine Learning Can Better ID Who Needs Lung Cancer Screening
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, Oct. 3, 2023 -- A machine learning model that uses only data on age, smoking duration, and pack-years can predict lung cancer risk and identify who needs lung cancer screening with better performance than currently used methods, according to a study published online Oct. 3 in PLOS Medicine.
Thomas Callender, Ph.D., from University College London, and colleagues developed and validated ensemble machine learning models to determine eligibility for risk-based lung cancer screening. The model was developed using data from 216,714 ever-smokers participating in the U.K. Biobank prospective cohort and 26,616 high-risk ever-smokers participating in the U.S. National Lung Screening randomized controlled trial. Validation used data from 49,593 participants in the chest radiography arm and all 80,659 ever-smoking participants in the U.S. Prostate, Lung, Colorectal, and Ovarian Screening Trial.
The researchers found that models predicting lung cancer death (UCL-D) and incidence (UCL-I) using three variables -- age, smoking duration, and pack-years -- achieved or exceeded parity in discrimination, overall performance, and net benefit versus comparators currently in use. In external validation, UCL-D had an area under the receiver operating characteristic curve (AUC) of 0.803 and was well calibrated with an expected/observed (E/O) ratio of 1.05. For UCL-I, the external validation had an AUC of 0.787 and an E/O ratio of 1.0. At five-year risk thresholds of 0.68 percent for UCL-D and 1.17 for UCL-I, the sensitivity was 85.5 and 83.9 percent, respectively, which was higher than the U.S. Preventive Services Task Force 2021 criteria at the same specificity.
"Risk assessment for lung cancer screening can be simplified without reducing performance, potentially improving the uptake and effectiveness of national lung cancer screening programs, and therefore contributing to reducing deaths from lung cancer," the authors write.
Several authors disclosed ties to industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.